ProSomnus oral appliance cleared for Medicare reimbursement
By HME News Staff
Updated 9:33 AM CST, Mon December 19, 2022
SAN FRANCISCO – ProSomnus, Inc., which makes precision oral appliance therapy (OAT) devices for the treatment of obstructive sleep apnea (OSA), has announced that its ProSomnus EVO {PH] Sleep and Snore Device now qualifies for Medicare reimbursement. The Pricing, Data Analysis, and Coding (PDAC) contractor has reviewed and verified the device for HCPCS code E0486. “With Medicare coding verification, the ProSomnus EVO [PH] offers health care providers and their Medicare beneficiary patients a comfortable, effective and reimbursable treatment option for OSA that addresses many of the limitations of dental product and CPAP therapies,” said Len Liptak, co-founder and CEO of ProSomnus. “Achieving Medicare coding verification for the ProSomnus EVO [PH] enhances our momentum as we expand availability of precision OAT to even more patients, thereby increasing adoption and creating better patient outcomes when treating OSA, a disease state impacting 74 million Americans today.” The ProSomnus EVO [PH] is a precision OAT medical device specifically engineered to meet CMS coding guidelines, offering Medicare beneficiaries a non-invasive, comfortable, easy-to-use and effective alternative to CPAP machines, surgical procedures, and legacy dental products, the company says. Per Medicare coding guidelines, the device repositions and stabilizes the patient’s jaw during sleep, increasing pharyngeal space and reducing the risk of upper airway collapse.
Comments